Results 21 to 30 of about 270,476 (268)
Nanopore sequencing approach for immunoglobulin gene analysis in chronic lymphocytic leukemia
Scientific Reports, 2021 The evaluation of the somatic hypermutation of the clonotypic immunoglobulin heavy variable gene has become essential in the therapeutic management in chronic lymphocytic leukemia patients.
Crescenzio Francesco Minervini +15 more
doaj +1 more source
Stem cell transplantation for neuroblastoma [PDF]
Bone Marrow Transplantation, 2007 High-risk neuroblastoma is a childhood malignancy with a poor prognosis. Gradual improvements in survival have correlated with therapeutic intensity, and the ability to harvest, process and store autologous hematopoietic stem cells has allowed for dose intensification beyond marrow tolerance.
J D, Fish, S A, Grupp
openaire +2 more sources
HaematologicaWe compared long-term outcomes in 78 patients with steroid-refractory acute graft-versushost disease (SR-aGVHD) treated at the University Medical Center Hamburg, Germany between December 2015 and August 2022 who received either ruxolitinib alone (Ruxo ...
Iryna Lastovytska +14 more
doaj +1 more source
Hemato, 2023 Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML), granting patients a life expectancy close to that of the normal population and, in a subset of patients, the possibility to discontinue therapy ...
Mario Tiribelli +11 more
doaj +1 more source
Autologous Stem Cell Transplantations
Annals of Medicine, 1996 High-dose treatments with autologous stem cell support have increasingly been used to improve the treatment results of a variety of haematological and nonhaematological malignancies. High-dose treatments cause severe bone marrow injury, which can effectively be rescued with infusion of a sufficient number of stem cells. Stem cells can be collected from
K, Remes, A, Rajamäki
openaire +2 more sources
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, with an overall survival now surpassing 90% in developed countries. However, treatments are not without adverse effects. In this study, we apply the severe toxicity‐free survival (STFS) framework to determine the prevalence of 21 physician‐defined severe ...
Lane Collier +10 more
wiley +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT In 2018, the Texas Children's Cancer and Hematology Center Leukemia Program implemented a practice standard to support the transition from treatment to survivorship that includes shared, alternating care between leukemia and survivorship clinicians and a reminder to refer survivors to the long‐term survivor clinic (LTSC) 2 years after ...
Ji Yun Tark +9 more
wiley +1 more source
Personalized Zebrafish Models for Fusion‐Positive Pediatric Sarcomas
Pediatric Blood &Cancer, EarlyView.ABSTRACT Clinical sequencing efforts have revolutionized our approaches to categorizing pediatric cancers in real time. This has dramatically improved our ability to profile pediatric tumors, identify actionable vulnerabilities, and influence clinical care.
Lisa H. Hall +2 more
wiley +1 more source
Haematologica, 2023 Treatment options for relapsed and refractory acute myeloid leukemia patients (R/R AML) are limited. This retrospective cohort study compares safety and efficacy of fludarabine, cytarabine, and idarubicin (FLA-IDA) without or with venetoclax (FLAVIDA ...
Rabia Shahswar +19 more
doaj +1 more source
The Role of “Adult‐Onset” Cancer Predisposition Genes in Pediatric Cancer: A Comprehensive Review
Pediatric Blood &Cancer, EarlyView.ABSTRACT Current literature estimates that 10% of pediatric cancers are caused by pathogenic or likely pathogenic (P/LP) germline variants in cancer predisposition genes (CPGs). Variants in CPGs thought to increase cancer risk exclusively during adulthood are referred to as “adult‐onset” CPGs (aoCPGs).
Maria Rozo +5 more
wiley +1 more source